News Kailera, Hengrui stake claim to oral weight loss category Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.
News $600m round will help Kailera push obesity drug into phase 3 Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.
News Hengrui to file obesity shot in China after phase 3 win An obesity therapy developed by Hengrui Pharma and Kailera is being prepared for its first regulatory submission, in China.
News Euro VCs team up to invigorate life sciences ecosystem Major venture capital groups in Europe have joined forces to set up a new coalition aimed at revitalising access to life sciences investment.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.